Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infectionMichael Kaleko, Sheila Connelly, Giovanni Widmer et al.|Anaerobe|2016Cited by 71
SYN-004 (ribaxamase), an oral beta-lactamase, mitigates antibiotic-mediated dysbiosis in a porcine gut microbiome modelSheila Connelly, Michael Kaleko, J. Andrew Bristol et al.|Journal of Applied Microbiology|2017Cited by 41